EZH1
Overview
EZH1 (Enhancer of Zeste Homolog 1) encodes a catalytic subunit of PRC2 (Polycomb Repressive Complex 2) that can methylate H3K27, functioning as a partial functional substitute for EZH2. In malignant peripheral nerve sheath tumors (MPNSTs), EZH1 was explicitly examined but found to be unaltered, distinguishing MPNST from contexts where EZH catalytic subunits are targeted.
Alterations observed in the corpus
- No alterations detected in any MPNST in the discovery or validation cohorts; explicit negative finding for this PRC2 catalytic subunit PMID:25240281.
Cancer types (linked)
- MPNST: not altered; PRC2 loss in MPNST occurs exclusively via EED or SUZ12 structural subunit inactivation, not via EZH1 or EZH2 PMID:25240281.
Co-occurrence and mutual exclusivity
- No co-occurrence data; explicitly unaltered in MPNST while EED and SUZ12 are recurrently inactivated PMID:25240281.
Therapeutic relevance
- Not directly implicated as a therapeutic target in the corpus.
Open questions
- Whether EZH1 activity compensates for EZH2 loss in other cancer contexts is not addressed in this study.
Sources
This page was processed by entity-page-writer on 2026-05-11.